3.10
price down icon6.20%   -0.205
 
loading
전일 마감가:
$3.305
열려 있는:
$3.39
하루 거래량:
204.44K
Relative Volume:
1.87
시가총액:
$44.06M
수익:
$134.00K
순이익/손실:
$-33.51M
주가수익비율:
-0.9665
EPS:
-3.2074
순현금흐름:
$-18.15M
1주 성능:
-19.69%
1개월 성능:
-19.69%
6개월 성능:
-51.18%
1년 성능:
-62.42%
1일 변동 폭
Value
$3.0152
$3.39
1주일 범위
Value
$3.0152
$3.93
52주 변동 폭
Value
$3.0152
$13.50

Clene Inc Stock (CLNN) Company Profile

Name
명칭
Clene Inc
Name
전화
801-676-9695
Name
주소
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Name
직원
79
Name
트위터
Name
다음 수익 날짜
2026-11-12
Name
최신 SEC 제출 서류
Name
CLNN's Discussions on Twitter

Compare CLNN vs VRTX, MRNA, REGN, ARGX, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
CLNN icon
CLNN
Clene Inc
3.10 44.06M 134.00K -33.51M -18.15M -3.2074
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Clene Inc Stock (CLNN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-10-04 다운그레이드 Oppenheimer Outperform → Perform
2022-07-18 개시 H.C. Wainwright Buy
2022-05-02 개시 Canaccord Genuity Buy
2021-09-28 개시 Oppenheimer Outperform

Clene Inc 주식(CLNN)의 최신 뉴스

pulisher
Oct 13, 2026

Two parties report shared voting power over 221,660 shares in Clene (CLNN). - Stock Titan

Oct 13, 2026
pulisher
Sep 21, 2026

A $4 million raise is expected to carry an ALS biotech past a potential FDA decision - Stock Titan

Sep 21, 2026
pulisher
Sep 18, 2026

Insider-linked LLC acquires new Clene (CLNN) shares - Stock Titan

Sep 18, 2026
pulisher
Sep 18, 2026

Clene (CLNN) CEO buys more stock in board-approved deal - Stock Titan

Sep 18, 2026
pulisher
Sep 16, 2026

Insiders back new funding round at Clene Inc. (CLNN) to support lead drug filing - Stock Titan

Sep 16, 2026
pulisher
Sep 15, 2026

A biotech's $4 million stock offering is expected to fund operations into 2027 - Stock Titan

Sep 15, 2026
pulisher
Sep 09, 2026

Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com India

Sep 09, 2026
pulisher
Sep 09, 2026

Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com UK

Sep 09, 2026
pulisher
Sep 03, 2026

Clene to Present at Upcoming September Investor Conferences - Investing News Network

Sep 03, 2026
pulisher
Sep 03, 2026

Clene to Present at Upcoming September Investor Conferences - manilatimes.net

Sep 03, 2026
pulisher
Sep 03, 2026

Two investor conferences in New York will hear from Clene this month - Stock Titan

Sep 03, 2026
pulisher
Aug 29, 2026

CLENE Q2 BASIC EPS USD -1.08 - Moomoo

Aug 29, 2026
pulisher
Aug 23, 2026

Clene (CLNN) Financial Results: EPS Prints Above Forecast in the Latest Reading; Trading Move: Shares Finish 1.14% Down at the CloseNext Quarter Guidance - vinanet.vn

Aug 23, 2026
pulisher
Aug 20, 2026

Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN) - The Globe and Mail

Aug 20, 2026
pulisher
Aug 20, 2026

Clene (CLNN) Outlook: Adds 4.30% to Close at $4.37 at the Close; Price Context: the Near-Term Reference Band Stretches From $4.15 to $4.59 under the Current SnapshotQuote Data - vinanet.vn

Aug 20, 2026
pulisher
Aug 19, 2026

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - MarketBeat

Aug 19, 2026
pulisher
Aug 19, 2026

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - Yahoo Finance

Aug 19, 2026
pulisher
Aug 19, 2026

Clene at Emerging Growth Conference: FDA path takes shape for ALS drug - Investing.com

Aug 19, 2026
pulisher
Aug 19, 2026

CLNN: CNM-Au8 shows strong survival and functional benefits in ALS, with NDA submission imminent - TradingView

Aug 19, 2026
pulisher
Aug 19, 2026

Clene (CLNN) Move: Climbs 0.49% to $4.11 on the Day; Technical Setup: $3.90 and $4.32 Define the Nearby Reference Levels for the Current SessionVWAP Deviation - vinanet.vn

Aug 19, 2026
pulisher
Aug 18, 2026

Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream - Investing News Network

Aug 18, 2026
pulisher
Aug 18, 2026

HC Wainwright Issues Negative Estimate for Clene Earnings - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

Clene (NasdaqCM:CLNN) Stock Forecast & Analyst Predictions - simplywall.st

Aug 18, 2026
pulisher
Aug 18, 2026

Clene(CLNN) Stock Options Chain | Quotes & News - Moomoo

Aug 18, 2026
pulisher
Aug 17, 2026

Clene to Present at the Emerging Growth Conference - Investing News Network

Aug 17, 2026
pulisher
Aug 17, 2026

Clene stock holds at buy as H.C. Wainwright keeps $31 target By Investing.com - Investing.com Australia

Aug 17, 2026
pulisher
Aug 17, 2026

Clene to Present at the Emerging Growth Conference - marketscreener.com

Aug 17, 2026
pulisher
Aug 17, 2026

Clene schedules a 3:10 p.m. webcast—what will it cover? - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com

Aug 17, 2026
pulisher
Aug 17, 2026

Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Australia

Aug 17, 2026
pulisher
Aug 17, 2026

Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Nigeria

Aug 17, 2026
pulisher
Aug 17, 2026

Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Canada

Aug 17, 2026
pulisher
Aug 17, 2026

Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com

Aug 17, 2026
pulisher
Aug 17, 2026

Clene to Present at the Emerging Growth Conference - The Manila Times

Aug 17, 2026
pulisher
Aug 16, 2026

Clene (NASDAQ:CLNN): Why Is Evidence And Funding in Focus Today? - Kalkine Media

Aug 16, 2026
pulisher
Aug 16, 2026

Clene (NASDAQ:CLNN): Why Is Clinical Evidence in Focus Today? - Kalkine Media

Aug 16, 2026
pulisher
Aug 16, 2026

CLNN Looks 375.9% Overvalued on GF Value™ - GuruFocus

Aug 16, 2026
pulisher
Aug 14, 2026

Clene earnings missed by $0.75, revenue topped estimates - Investing.com

Aug 14, 2026
pulisher
Aug 14, 2026

Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS - MarketBeat

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026
pulisher
Aug 14, 2026

Vivo Opportunity entities disclose 9.99% Clene Inc. (CLNN) stake via warrants - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Inc. (CLNN) grants 3,195 stock options to director Matthew Kiernan - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Inc. (CLNN) grants 4,872 stock options to director Alison Mosca - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Inc. (CLNN) grants director Arjun Desai 3,674 options at $4.19 strike - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Inc. (CLNN) director receives 6,230 stock options at $4.19 strike - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Inc. (CLNN) awards director Shalom Jacobovitz 4,752 stock options at $4.19 - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Inc. (CLNN) director receives 3,514 stock options vesting immediately at $4.19 - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Inc. (CLNN) director granted 3,514 stock options at $4.19 strike - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Clene Q2 FY26 net loss widens 81% to $13.42 million - Bitget

Aug 14, 2026

Clene Inc (CLNN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Clene Inc 주식 (CLNN) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Ugwumba Chidozie
10% Owner
May 11 '26
Sale
6.75
22,177
149,695
176,713
Symbiosis II LLC
Former Board Member
May 11 '26
Proposed Sale
6.50
198,890
1,292,785
0
Ugwumba Chidozie
10% Owner
May 04 '26
Sale
6.80
72,884
495,611
198,890
Symbiosis II LLC
Former Board Member
May 04 '26
Proposed Sale
6.55
41,260
270,381
0
Ugwumba Chidozie
10% Owner
May 01 '26
Sale
6.01
5,795
34,828
271,774
Ugwumba Chidozie
10% Owner
Apr 30 '26
Sale
6.08
5,736
34,875
277,569
Ugwumba Chidozie
10% Owner
Apr 29 '26
Sale
5.63
12,170
68,517
283,305
Ugwumba Chidozie
10% Owner
Apr 28 '26
Sale
5.90
1,591
9,387
295,475
Symbiosis II LLC
Former Board Member
Apr 28 '26
Proposed Sale
5.90
56,916
335,804
0
Ugwumba Chidozie
10% Owner
Apr 21 '26
Sale
6.14
61,345
376,658
297,066
$6.58
price down icon 4.22%
$9.94
price down icon 3.21%
$5.53
price down icon 3.66%
$11.27
price down icon 6.16%
$18.60
price down icon 1.74%
WVE WVE
$3.13
price down icon 1.88%
자본화:     |  볼륨(24시간):